Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
124 hedge funds and large institutions have $968M invested in Genomic Health, Inc. in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 43 increasing their positions, 47 reducing their positions, and 16 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
9% more capital invested
Capital invested by funds: $892M → $968M (+$76.1M)
9% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 47
7% less funds holding
Funds holding: 133 → 124 (-9)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$69.4M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$9.83M |
| 3 |
Renaissance Technologies
New York
|
+$4.63M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$4.45M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$10.1M |
| 2 |
Morgan Stanley
New York
|
-$2.77M |
| 3 |
CCMH
Cornerstone Capital Management Holdings
New York
|
-$1.7M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.62M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.37M |
GHDX Hedge Fund Activity: Q1 2017 in Review
124 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q1 2017, worth a combined $968M — up 8.5% from $892M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GHDX and 14 opened new positions — a net loss of 2 holders — while 47 trimmed existing stakes and 43 added.
The largest buyer was BlackRock, adding an estimated $69.4M. The largest seller was Millennium Management, cutting an estimated $10.1M.
- 124 institutional investors held Genomic Health, Inc. (GHDX) as of Q1 2017, down from 133 in Q4 2016.
- Funds reported $968M of Genomic Health, Inc. stock for Q1 2017, up 8.5% quarter-over-quarter.
- 14 funds opened new Genomic Health, Inc. positions in Q1 2017 and 16 closed out, a net change of -2 holders.
- The largest Genomic Health, Inc. buyer in Q1 2017 was BlackRock, an estimated $69.4M added.
- The largest Genomic Health, Inc. seller in Q1 2017 was Millennium Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q1 2017.